These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
163 related articles for article (PubMed ID: 4067207)
1. Pseudotumor cerebri and thyroid-replacement therapy in patients affected by differentiated thyroid carcinoma. Panza N; De Rosa M; Lombardi G; Salvatore M J Endocrinol Invest; 1985 Aug; 8(4):357-8. PubMed ID: 4067207 [TBL] [Abstract][Full Text] [Related]
2. [Therapy of differentiated thyroid carcinomas. Prospective study]. Gemsenjäger E; Staub JJ; Heitz PU Schweiz Med Wochenschr; 1985 Feb; 115(5):153-9. PubMed ID: 3975583 [TBL] [Abstract][Full Text] [Related]
5. Thyroid cancer in a case with the Alagille syndrome. Kato Z; Asano J; Kato T; Yamaguchi S; Kondo N; Orii T Clin Genet; 1994 Jan; 45(1):21-4. PubMed ID: 8149647 [TBL] [Abstract][Full Text] [Related]
7. Management of coexisting thyrotropin/growth-hormone-secreting pituitary adenoma and papillary thyroid carcinoma: a therapeutic challenge. Nguyen HD; Galitz MS; Mai VQ; Clyde PW; Glister BC; Shakir MK Thyroid; 2010 Jan; 20(1):99-103. PubMed ID: 20067380 [TBL] [Abstract][Full Text] [Related]
8. Bone mineral density in patients receiving suppressive doses of thyroxine for thyroid carcinoma. Florkowski CM; Brownlie BE; Elliot JR; Ayling EM; Turner JG N Z Med J; 1993 Oct; 106(966):443-4. PubMed ID: 8233173 [TBL] [Abstract][Full Text] [Related]
9. The effect of thyroid hormone administration upon survival in patients with differentiated thyroid carcinoma. Cady B; Cohn K; Rossi RL; Sedgwick CE; Meissner WA; Werber J; Gelman RS Surgery; 1983 Dec; 94(6):978-83. PubMed ID: 6648813 [TBL] [Abstract][Full Text] [Related]
10. [Thyroiditic reactions during a course of thyroid cancer]. Palmieri B; Zambarda E; Borghi G; Cogni P Minerva Chir; 1977 Jan; 32(12):7-18. PubMed ID: 854207 [TBL] [Abstract][Full Text] [Related]
15. Quality of life and effectiveness comparisons of thyroxine withdrawal, triiodothyronine withdrawal, and recombinant thyroid-stimulating hormone administration for low-dose radioiodine remnant ablation of differentiated thyroid carcinoma. Lee J; Yun MJ; Nam KH; Chung WY; Soh EY; Park CS Thyroid; 2010 Feb; 20(2):173-9. PubMed ID: 20151824 [TBL] [Abstract][Full Text] [Related]
16. [Rare adverse effect of discontinuation of levothyroxine treatment for 131I ablation of thyroid remnant in a patient with differentiated thyroid cancer]. Luque-Ramírez M; Gómez Ramírez J; Azcárate Villalón A; Martín Pérez E; Larrañaga Barrera E Endocrinol Nutr; 2013; 60(7):412-4. PubMed ID: 23271037 [No Abstract] [Full Text] [Related]
17. Management of thyroid cancer of follicular cell origin: Gundersen/Lutheran Medical Center, 1969-1995. Martins RG; Caplan RH; Lambert PJ; Rooney B; Kisken WA J Am Coll Surg; 1997 Oct; 185(4):388-97. PubMed ID: 9328388 [TBL] [Abstract][Full Text] [Related]
18. Effect of suppressive therapy with levothyroxine on the reduction of serum thyroglobulin after total thyroidectomy. Rosario P; Borges M; Reis J; Alves MF Thyroid; 2006 Feb; 16(2):199-200. PubMed ID: 16676413 [No Abstract] [Full Text] [Related]